NDAINJECTIONINJECTABLE
Approved
May 1953
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
QUELICIN (succinylcholine chloride) by Pfizer is blocker. Approved for mechanical ventilation. First approved in 1953.
Drug data last refreshed 11h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
QUELICIN (succinylcholine chloride) is a depolarizing neuromuscular blocking agent approved in 1953 that binds to acetylcholine receptors at the motor end plate, causing rapid onset flaccid paralysis lasting 4–6 minutes. It is used to facilitate mechanical ventilation and endotracheal intubation in acute care settings. The drug works by mimicking acetylcholine, depolarizing muscle membranes and blocking subsequent neuromuscular transmission.
LOE Approaching
Product is in late-stage lifecycle with approaching loss of exclusivity; commercial teams are likely focused on cost management and market defense rather than expansion.
Mechanism of Action
blocker. As does acetylcholine, it combines with the cholinergic receptors of the motor end plate to produce depolarization. This depolarization may be observed as fasciculations. Subsequent neuromuscular transmission is inhibited so long as adequate concentration of succinylcholine remains at the…
Indications (1)
Worked on QUELICIN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.